Sometimes earnings experiences may be good, however the inventory value doesn't replicate that.
Zacks Funding Research upgraded shares of Fortress Biotech from a hold” rating to a strong-purchase” ranking and set a $2.50 goal worth for the company in a report on Friday, February 15th.